Even as Tesla continues to rake in the cash, it remains absent from the portfolios of auto ETFs�and broader consumer discretionary funds. One huge positive for investors who have so far used�alternative energy�funds to gain exposure to the growing firm, there are a number of funds that revolve around the NASDAQ 100. Many ETFs will have to pick up Tesla when they rebalance to continue tracking their index, allowing for ETF exposure that was missing for Tesla.
Alternative energy funds such as the NASDAQ Clean Edge Green Energy Index Fund� have already seen huge growth from not only the great year green energy has enjoyed, but the added bonus of heavy Tesla weightings to their portfolios. QCLN, which specifically tracks the technology firms working on clean energy components, has returned nearly 60% since the beginning of the year and 36% in just the last 13 weeks�.
Best Restaurant Stocks For 2015: Volcano Corporation(VOLC)
Volcano Corporation designs, develops, manufactures, and commercializes intravascular ultrasound (IVUS) and fractional flow reserve (FFR) products used in the diagnosis and treatment of vascular and structural heart disease. It offers multi-modality consoles, which are marketed as stand-alone units that can be integrated into hospital-based interventional surgical suites, such as catheterization laboratories. The company provides IVUS products, including single-procedure disposable phased array and rotational IVUS imaging catheters; and additional functionality options comprising virtual histology tissue characterization, and ChromaFlo stent apposition analysis. It also offers FFR products, such as pressure and flow consoles, and single-procedure disposable pressure and flow guide wires used to measure the pressure and flow characteristics of blood around plaque enabling physicians to gauge the plaque?s physiological impact on blood flow and pressure. In addition, the com pany develops and manufactures optical monitors for the telecommunication industry; laser and non-laser light sources; optical engines used in the medical OCT imaging systems and advanced photonic components; and sub-systems used in spectroscopy and other industrial applications. Its products under development include image-guided therapy device and micro and thrombectomy catheters. The company?s ongoing clinical studies comprise assessment of dual anti-platelet therapy with drug-eluting stents; vascular evaluation for revascularization; fractional flow reserve and intravascular ultrasound relationship study; adensonine vasodilation independent stenosis evaluation; and evaluation of XIENCE PRIME. It sells its products through direct sales force and distributors, as well as through third parties supply and distribution agreements primarily in the United States, Japan, Europe, the Middle East, Africa, and internationally. The company was founded in 2000 and is headquartered i n San Diego, California.
Advisors' Opinion:- [By Ali Berri]
Volcano (NASDAQ: VOLC) shares tumbled 23.57 percent to $12.06 on Q2 results. The company reported Q2 earnings of $0.01 per share on revenue of $102.60 million. Volcano announced its plans to divest its Axsun Technologies subsidiary and also announced the litigation settlement agreement with St. Jude Medical (NYSE: STJ). Oppenheimer downgraded Volcano from Outperform to Market Perform and lowered the price target from $22.00 to $15.00.
Top Clean Energy Companies To Buy Right Now: Protalix Biotherapeutics Inc (PLX)
Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system, ProCellEx. Using its ProCellEx system, the Company is developing a pipeline of biosimilar or generic versions of recombinant therapeutic proteins based on its plant cell-based expression technology, which focuses pharmaceutical markets and that rely upon known biological mechanisms of action. ProCellEx protein expression system consists of a set of technologies and capabilities for the development of recombinant proteins, including advanced genetic engineering technology and plant cell-based protein expression methods. Its ProCellEx protein expression system is built on flexible custom-designed bioreactors made of polyethylene and optimized for the development of complex proteins in plant cell cultures. In June 2010, it had completed the preliminary phase I clinical trial of PRX-105.
Taliglucerase Alfa
Taliglucerase alfa is a plant cell expressed recombinant glucocerebrosidase enzyme (GCD) for the treatment of Gaucher disease. The Company has commenced pre-clinical studies of an oral form of taliglucerase alfa. Its oral taliglucerase alfa is a plant cell expressed form of GCD that is naturally encapsulated within carrot cells genetically engineered to express the GCD enzyme. Pre-clinical studies of oral taliglucerase alfa demonstrate the stability of the enzyme in the cell and the capacity of the cell�� cellulose wall to protect the enzyme against degradation in the digestive tract in an in-vitro model of the stomach and intestines. Additionally, rats fed with lyophilized carrot cells expressing GCD have accumulated the active enzyme in the target organs; the spleen and liver. As of December 31, 2010, the Company had completed Phase III Clinical Trial.
PRX-102
The Company is developing PRX-102, its plant cell expressed modified version of the recombinant ! alpha-GAL-A protein, a therapeutic enzyme for the treatment of Fabry disease. Fabry disease is a rare, hereditary, genetic lysosomal storage disorder in humans caused by an X-lined deficiency of the alpha-GAL-A enzyme. The Company is in the animal evaluation testing phase of the development of PRX-102, which tests are based on a mouse model for Fabry disease.
Acetylcholinesterase
Protalix Ltd. is a wholly owned subsidiary of the Company is licensed the rights to certain technology under a research and license agreement with Yissum Research and Development Company (Yissum) and the Boyce Thompson Institute, Inc. Pursuant to the agreement, the Company is developing PRX-105, a plant cell-based acetylcholinesterase (AChE) and its molecular variants for the use in several therapeutic and prophylactic indications, as well as in a biodefense program and an organophosphate-based pesticide treatment program.
As of December 31, 2010, its in-vitro experiments of PRX-105 have shown that the acetylcholinesterase enzyme in its ProCellEx protein expression system demonstrates biological activity on biochemical and cellular levels. In addition, early animal studies demonstrated that the acetylcholinesterase expressed in its ProCellEx protein expression system was able to treat animals exposed to the nerve gas agent analogues, both when injected with its acetylcholinesterase product candidate immediately before exposure or when injected after exposure. In March 2010, it initiated a preliminary phase I clinical trial of PRX-105, which the Company completed in June 2010.
pr-antiTNF
pr-antiTNF is a candidate for the treatment of certain autoimmune diseases such as rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing, spondylitis, psoriatic arthritis and plaque psoriasis. The Company has designed the antiTNF as pr-antiTNF. pr-antiTNF is a plant cell-expressed recombinant fusion protein made from the soluble form of the human TNF receptor (TNFR), f! used to t! he Fc component of a human antibody domain. pr-antiTNF has an identical amino acid sequence to Enbrel and its in-vitro and preclinical animal studies have demonstrated that pr-antiTNF exhibits similar activity to Enbrel. Specifically, pr-antiTNF binds TNF thereby inhibiting it from binding to cellular surface TNF receptors and protects L929 cells from TNF-induced apoptosis in a dose-dependent manner.
The Company competes with Genzyme, Actelion, Crucell N.V., Biolex, Inc., Chlorogen, Inc., Greenovation Biotech GmbH, Symbiosys, Novartis AG/Sandoz Pharmaceuticals, BioGeneriX AG, Stada Arzneimittel AG, BioPartners GmbH and Teva.
Advisors' Opinion:- [By Keith Speights]
Other investors might wish that Pfizer would use some of its cash to acquire a few smaller companies. Protalix BioTherapeutics (NYSEMKT: PLX ) has been mentioned as one possible candidate. The two companies already partner together on Gaucher disease drug Elelyso. In February, Protalix spurred rumors that Pfizer could be interested in buying the company after it announced that it had engaged Citigroup to pursue a "broad array of strategic alternatives."
Top Clean Energy Companies To Buy Right Now: Microchip Technology Incorporated(MCHP)
Microchip Technology Incorporated, together with its subsidiaries, develops, manufactures, and sells semiconductor products for various embedded control applications. It offers a family of microcontroller products that include 8-bit, 16-bit, and 32-bit PIC microcontrollers; and 16-bit dsPIC digital signal controllers, which feature on-board flash memory technology. The company also provides a set of application development tools that enable system designers to program a PIC microcontroller and dsPIC DSC for specific applications. In addition, it offers analog and interface products, which consist of various families with approximately 600 power management, linear, mixed-signal, thermal management, safety and security, and interface products. Further, the company provides memory products comprising serial electrically erasable programmable read-only memory. Its products are used in various applications in automotive, communications, computing, consumer, and industrial contr ol markets. Microchip Technology Incorporated markets its products primarily through a network of direct sales personnel and distributors in the Americas, Europe, and Asia. The company was founded in 1989 and is based in Chandler, Arizona.
Advisors' Opinion:- [By Riddhi Kharkia]
The semiconductor maker had it pretty bad on Friday as most of the stocks fell after the warning from Microchip Technology Inc. (MCHP). Though it might have looked like an overreaction yet, the investors of semiconductor stocks had to face a reasonable depreciation in their investment value because Microchip cut its sales outlook and warned investors that the industry could face a downturn pretty soon. Well, this is a thing of the past and what is done cannot be undone but the important thing to worry about is future. Intel (INTC), the chip giant which has been gaining momentum and has performed better than expectations in the year, is all set to post its third-quarter earnings on Tuesday.
Top Clean Energy Companies To Buy Right Now: Carrefour SA (CRERF)
Carrefour SA is a France-based company that is primarily engaged in retail distribution sector. The Company operates a network of hypermarkets, supermarkets, hard discount stores, convenience stores and cash-and-carry outlets and offers e-commerce services. The Company's hypermarkets named Carrefour offer a range of food and non-food products. Carrefour SA�� hypermarkets, supermarkets and convenience stores are operating under the Carrefour city, Carrefour contact, Carrefour express, 8aHuit, Shopi, Marche Plus, Proxi banners and cash & carry stores are operating under the Promocash banner, which primarily offer food, clothing and household goods, among others. The Company operates in mainland France and French overseas territories, as well as in Europe, Asia, Latin America, North Africa and the Middle East through a network of consolidated and franchised stores, and stores that Carrefour SA runs with partner companies. In January 2014, it acquired 129 convenience stores. Advisors' Opinion:- [By Sophia Yan]
Carrefour (CRERF) has also shuttered many stores, and is reported to be exploring a sale of its China and Taiwan businesses.
Hypermarkets -- big box stores that combine supermarkets and department stores -- first opened up in China's largest cities over a decade ago. And it's no wonder companies such as Wal-Mart have been keen to get a slice of the market.
Top Clean Energy Companies To Buy Right Now: Intuit Inc.(INTU)
Intuit Inc. provides business and financial management solutions for small and medium-sized businesses, consumers, accounting professionals, and financial institutions primarily in the United States, Canada, India, Singapore, and the United Kingdom. The company offers QuickBooks financial and business management software and services, technical support, financial supplies, and Web site design and hosting services for small and medium-sized businesses; and payroll products and services, as well as merchant services comprising credit and debit card processing, electronic check conversion, and automated clearing house services for small businesses. It also provides TurboTax income tax preparation products and services for consumers and small business owners; Lacerte and ProSeries professional tax products and services; and QuickBooks Premier Accountant Edition and the QuickBooks ProAdvisor Program for accounting professionals. In addition, the company offers outsourced online financial management solutions for banks and credit unions; Quicken personal finance products and services; Mint.com online personal finance services; and Intuit Health online patient-to-provider communication solutions. It sells its products and services through various sales and distribution channels, including Websites, promotions, retail channels, and call centers, as well as through alliance partners, principally consisting of banks, credit unions, and securities and investment firms. The company was founded in 1983 and is headquartered in Mountain View, California.
Advisors' Opinion:- [By Selena Maranjian]
When looking for promising candidates for your stock portfolio, it's easy to just think about the prominent names of the day, such as Facebook, Ford, or Bank of America. But there are plenty of other possibilities, many of which have been under our nose for quite some time.
Here's a key reason you may want to keep reading -- ADP stock's performance: It's up about 33% over the past year, and has averaged annual gains of 13.6% �over the past 30 years. Great performances are never guaranteed, but this company's management clearly knows a thing or two about executing well.�
Permit me to introduce you to Automatic Data Processing (NASDAQ: ADP ) , often referred to as ADP. Here are a bunch of interesting things about ADP the company and ADP stock.
� The basics: The company began in 1949 �as Automatic Payrolls, based in New Jersey. It aimed to assist companies with some of their payroll and related processes by applying technology. Today, still based in New Jersey, it's an outsourcing powerhouse, with a market capitalization near $35 billion. (One of its closest competitors is Paychex (NASDAQ: PAYX ) , with a market cap of just $14 billion.) It serves some 600,000 customers in more than 125 nations and rakes in more than $11 billion annually, keeping about 13% of that, more than $1.4 billion, as net profit.
� ADP is of interest to many more people than just holders (or would-be holders) of ADP stock. That's because, since it serves such a significant chunk of American employers, cutting many millions of paychecks, it has its finger on the pulse of our economy. Thus, the company regularly issues national employment reports. (In early July, it reported private-sector employment rising by 188,000 jobs in June.)
� As a business, ADP has grown both in size and depth. In its own history, it notes that in the 1990s, "clients that once were content to outsource applications to a service provider looked to outsource entir - [By Rich Smith]
ADP stock is worse than average
ADP shares have been on a bit of a tear these past 12 months, outperforming not just the S&P 500 in general, but also rivals Paychex (NASDAQ: PAYX ) and Intuit (NASDAQ: INTU ) in particular. It's a bit of a mystery, however, understanding why investors like ADP stock so much. - [By Dan Caplinger]
Meanwhile, Intuit (NASDAQ: INTU ) hasn't been standing still either. It caters to customers who want automated solutions like its QuickBooks software rather than full-service HR coverage, but by trying to offer those customers more services, Intuit already has inroads with those customers and could eventually lure Paychex clients over to its side as well.
- [By Laura Brodbeck]
Thursday
Earnings Expected From: Salesforce.com (NYSE: CRM), Intuit (NASDAQ: INTU), Gap (NYSE: GPS), Dollar Tree (NASDAQ: DLTR), Hormel Foods (NYSE: HRL), Gamestop (NYSE: GME) Economic Releases Expected: U.S. existing home sales, eurozone consumer confidence, U.S. manufacturing PMI, British retail sales, eurozone manufacturing PMI, eurozone services PMI, German manufacturing PMI, German services PMI, French manufacturing PMI, French services PMIFriday
Top Clean Energy Companies To Buy Right Now: EveryWare Global Inc (EVRY)
EveryWare Global, Inc., formerly ROI Acquisition Corp., incorporated on September 19, 2011, is the designer and seller of tabletop and food preparation products for the consumer and foodservice markets. The Company�� global platform allows the Company to market and distribute internationally its total portfolio of products, including flatware, dinnerware, crystal stemware, glassware, serveware, cutlery, buffetware, candle glass, floral glass, spirit bottles, kitchen tools and gadgets and kitchen accessories. On June 18, 2013, the Company acquired the George Wilkinson and Samuel Groves business units of Metalrax Housewares, a maker and provider of metal bakeware, cooking utensils and catering supplies.
The Company also licenses the trademarks and distributes the Stolzle, Schonwald, Strata and BuffetEuro branded products in its Consumer, Foodservice and International segments. The Company operates in the United States, Canada, Mexico, Latin America, Europe and Asia.
Advisors' Opinion:- [By John Udovich]
On Wednesday, small cap kitchen stock Everyware Global Inc (NASDAQ: EVRY) surged 52.94% after announcing an amendment to extend its forbearance agreement with lenders until July 15 that could give the company�time to find a long-term financing solution���meanings its worth taking as closer look at the stock along with potential peers Libbey Inc (NYSEMKT: LBY) and Lifetime Brands Inc (NASDAQ: LCUT).
Top Clean Energy Companies To Buy Right Now: Neurocrine Biosciences Inc.(NBIX)
Neurocrine Biosciences, Inc. engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. It develops drugs for endometriosis, stress-related disorders, pain, tardive dyskinesia, uterine fibroids, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. The company?s products in clinical development include Elagolix, a Phase II drug for endometriosis; Vesicular Monoamine Transporter 2 Inhibitor (VMAT2), a Phase II drug for movement disorders; CRF2 Peptide Agonist, a Phase II drug for cardiovascular diseases; CRF1 Antagonist, a Phase II drug for stress-related disorders; and Elagolix, a Phase II drug for uterine fibroids. Its research programs comprise G Protein-Coupled Receptor 119 (GPR119) for type II diabetes; VMAT2 for schizophrenia; GnRH Antagonists for men?s and women?s health, and oncology; Antiepileptic Drugs for epilepsy, essential tremor, and pain; and G Protein-Coupled Receptors for other conditions. The company has collaborations with GlaxoSmithKline to develop and commercialize CRF antagonists for psychiatric, neurological, and gastrointestinal diseases; Dainippon Sumitomo Pharma Co. Ltd. to develop and commercialize Indiplon in Japan; Abbott International Luxembourg S.�r.l. to develop and commercialize elagolix and GnRH antagonists for women?s and men?s health indications; and Boehringer Ingelheim International GmbH to research, develop, and commercialize small molecule GPR119 agonists for the treatment of type II diabetes and other indications. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
Advisors' Opinion:- [By John Udovich]
Yesterday, small cap biopharmaceutical stock Neurocrine Biosciences, Inc (NASDAQ: NBIX) surged 89.69% after announcing positive results for its VMAT2 inhibitor NBI-98854 as a treatment for tardive dyskinesia, meaning investors late to the party or those already in should take a closer look at the stock along with its performance verses that of biotech ETFs like the iShares NASDAQ Biotechnology Index ETF (NASDAQ: IBB) and SPDR S&P Biotech ETF (NYSEARCA: XBI).
- [By Roberto Pedone]
Another stock that's starting to trend within range of triggering a major breakout trade is Neurocrine Biosciences (NBIX), which discovers, develops and commercializes drugs for the treatment of neurological and endocrine-related diseases and disorders. This stock has been a hot name with bulls so far in 2013, with shares up 57%.
If you look at the chart for Neurocrine Biosciences, you'll notice that this stock recently gapped down sharply from $16.74 to below $11.50 a share with heavy downside volume flows. Following that gap down, shares of NBIX went on to continue its trend lower and the stock hit a new low of $10.42 a share. Shares of NBIX have started to rebound off that $10.42 low and it's now moving within range of triggering a major breakout trade.
Traders should now look for long-biased trades in NBIX if it manages to break out above some near-term overhead resistance levels at its 200-day moving average of $11.92 a share and above its gap down day high of $12.17 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 894,145 shares. If that breakout triggers soon, then NBIX will set up to re-fill some of its previous gap down zone from September that started at $16.74 a share. Some possible upside targets for NBIX if it gets into that gap with volume are $14 to $15 a share.
Traders can look to buy NBIX off any weakness to anticipate that breakout and simply use a stop that sits right below support at $11 a share, or below that recent low of $10.42 a share. One can also buy NBIX off strength once it takes out that breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
- [By Ben Levisohn]
Yes, say the folks at Nomura, who recommend buying�Celgene (CELG), Receptos
(RCPT), Gilead Sciences (GILD), Neurocrine Biosciences (NBIX), and Alexion Pharmaceuticals (ALXN), in that order. Analyst M. Ian Somaiya and team explain why: - [By Lisa Levin]
Neurocrine Biosciences (NASDAQ: NBIX) shares moved up 76.95% to $17.27. The volume of Neurocrine Biosciences shares traded was 4406% higher than normal. Neurocrine Biosciences reported positive results of VMAT2 inhibitor NBI-98854 in Kinect 2 study.
No comments:
Post a Comment